TSG101: An Antiviral Target with a Murky Past

USURPING THE CELLULAR WHEELMAN © Russell Kightley Media, http://rkm.com.au/ Ebola (above) is a killer virus that may commandeer cellular protein-sorting pathways through TSG101. Viruses can't do much without a host. They propagate by usurping cellular machinery, and much of an infection's misery is due to the immune response. But conventional therapies, without much luck, essentially have targeted one-half of the infection equation: the foreign invader. Now, researchers increasingly are setting their sights on the host's role. Investigators recently attempted to mitigate the host immune response and the associated collateral damage (see sidebar). Some explore a complementary approach: to cut off access to the cellular pathway that a virus commandeers to mass-produce, specifically, the route used to bud from the cell. Doing so, without impairing the host, could provide a powerful new broad-spectrum antiviral agent. "Conventional antivirals are highly specific, and pathogens can mutate to insensitivity," says Stanley Cohen, professor of genetics and medicine at Stanford University. "But if one can attack host genes required for pathogens to be pathogenic, resistance is less likely. One can affect the pathogenicity of the virus." DUBIOUS BEGINNINGS Cohen, who with Herbert W. Boyer in the early 1970s essentially founded recombinant DNA technology, says he might have zeroed in on what may become the first such "host-oriented" therapeutic target: Tumor Susceptibility Gene 101. Despite its moniker, TSG101 may have less to do with cancer than first thought, and everything to do with the vacuolar protein-sorting pathway that ferries excess cell-surface receptors to lysosomes, the enzyme-filled sacs that dismantle debris. Certain killer viruses, including HIV, Ebola, and Marburg, hijack this transport system using TSG101 protein to cloak themselves in membranous escape pods. At least three biotech companies are developing drugs to target TSG101, which Cohen dubs "the getaway driver for viral release." But a clinical future awaits clarification of its obfuscated origins as a tumor suppressor. Discovering TSG101 in 1996 was the first fruit of random homozygous knockout (RHKO) technology, an antisense technique that identifies genes by a particular function, in this case, cellular transformation.1 Dampening TSG101 expression transformed murine 3T3 fibroblasts, which caused metastatic tumors in nude mice. The encoded protein bore the hallmarks of a transcription factor, but the links to carcinogenesis turned out to be indirect. THE VIRAL PIRATE In 2000, experimental roads converged to flesh out the role of TSG101. Beth Agresta, a graduate student working with molecular geneticist Carol Carter, State University of New York, Stony Brook, was screening for cellular proteins that interact with HIV proteins. "She got several hits and wrote her thesis on one, but continued to check the database to see if there was any more information. One day, there was," recalls Carter. That was TSG101. Carter and Cohen collaborated to get at protein function. Soon, another graduate student in Carter's group, Lynn Ver-Plank, identified the major viral core protein Gag as HIV's binding site for TSG101.2 Gag lets mature viruses bud from cells. At about the same time, Jennifer Garrus, a graduate student with biochemist Wesley Sundquist, University of Utah School of Medicine, Salt Lake City, blocked TSG101 with small interfering RNA, halting HIV budding. When she restored gene function, budding resumed.3 Gag and TSG101 attach by ubiquitin tags, and the host protein then escorts the viral emissary into the vacuolar protein-sorting pathway. But instead of being carted away to digestive doom in the lysosome, Gag proteins attach by their bound TSG101s to bits of cell membrane, ultimately becoming packaged into mature virions. Yeast provided another connection. Also in 2000, University of Utah biologist Markus Babst and Scott Emr, a Howard Hughes Medical Institute investigator at the University of California, San Diego, found that TSG101 has a yeast counterpart, Vps23.4 Vps23/TSG101 is a subunit of a complex, called ESCRT-I, which binds and sorts ubiquitin-tagged molecules. They tested Cohen's TSG101 mutant cell line for protein transport defects and found trafficking phenotypes, says Babst. The solid link to intracellular protein transport may explain the dual role of TSG101 in carcinogenesis and viral infection. The pathway normally recycles cell-surface receptors, including growth-factor receptors. Silence TSG101, and these receptors aren't sent to the lysosomal garbage dumps; instead they accumulate at the cell surface like uncollected trash. There, the receptors transduce too many signals to divide, and runaway mitosis results. But the cancer connection still is not as clear as some researchers would like. "The role of TSG101 in cancer has been quite elusive," says Sundquist, citing a retracted report on TSG101 mutations in cancer patients.5 And Kay-Uwe Wagner, at the Eppley Institute for Research in Cancer and Allied Diseases at the University of Nebraska Medical Center, Omaha, used knockout mice to show that TSG101 is essential for embryo implantation but not tumor suppression.6 She also reexamined the original 1996 tumorigenic cell line and found "whopping levels" of TSG101.7 She blames Cohen's use of an immortal cell line. "Nobody was able to repeat these transformation studies in other cell lines," she says. DRUG DEVELOPMENT Still, Cohen maintains that TSG101 makes a good antiviral target. He and former postdoctoral researcher Limin Li cofounded the company Functional Genetics, which is developing a viral budding inhibitor based on TSG101's action. But the jump from promising target in cell culture to antiviral development will not be easy. Such a drug probably would block normal ESCRT function as well, says Babst. "This could result in a tumorigenic phenotype." Effects could be wide-ranging. "I'm worried about the potential that a TSG101 inhibitor would exhibit general cytotoxicity," suggests Sundquist, who also works with Myriad Pharmaceuticals in Salt Lake City. Even if TSG101 never overcomes its tainted beginnings, it may still pioneer host-oriented therapeutics, for there may be unknown aspects of the viral subversion of TSG101 to exploit. Concludes Carter: "That's what one goes after – to understand the process, what the virus does to divert the machinery – and target that." Ricki Lewis rickilewis@nasw.org is a freelance writer in Scotia, NY. Fight the Flu, Ignore the Bug At the start of this year's particularly worrisome flu sea-son, researchers at London Imperial college in the United Kingdom posed a comforting thought. Suppose the bug's nasty symptoms could be avoided without vaccination or antiviral drugs by targeting the immune responses responsible for influenza's misery. Their tests on mice showed positive results, they say. Maybe so, say the skeptics, but that doesn't prove how humans would respond. The Imperial College researchers have found that a receptor molecule called OX40 is overexpressed in T cells responding to a viral infection, but not in the remaining T-cell population.1 The receptor can be blocked using an OX40-immunoglobulin fusion protein called OX40:Ig. This, the researchers say, should temper overzealous immune responses in the lungs. Tracy Hussell and colleagues, who tested the drug on mice injected with influenza type A, found that clinical symptoms such as congestion and high body temperature were virtually eliminated. Hussell says there's no reason why the treatment could not be extended to humans, after symptoms have emerged. "Mice could show signs of illness for three days, and as soon as you administer this reagent, it stops clinical symptoms in their tracks." In the future, humans could experience similar remission of symptoms, according to Alan Hay, director of the WHO Collaborating Centre for Reference and Research on Influenza at the UK National Institute for Medical Research. "It's interesting work, but it's early stages and needs further development," says Hay. Brad Magor, assistant professor, Department of Biological Sciences (Immunogenetics), University of Alberta, is more dubious. "Mice are not natural hosts to influenza A, so their response to the pathogen is less likely to reflect that of a natural host such as a chicken, swine, or human." Magor says he's concerned that the body might permanently lose influenza-specific memory cells as a result of the treatment. He conceded, however, that blocking OX40 molecules showed significant promise for modulating immunity and inducing tolerance to engrafted organs. Hussell says the group is focusing on the influenza treatment for now and is applying to the UK Medical Research Council and the Wellcome Trust for funding to begin human clinical trials. The Imperial College group collaborates with Xenova, a UK-based biotech that explores various therapeutic uses of OX40, including autoimmune disease and cancer. - Philip Hunter "A critical role for OX40 in T cell-mediated immunopathology during lung viral infection," Humphreys IR, J Exp Med Vol 198, 1237-42 Oct. 20, 2003

TSG101: An Antiviral Target with a Murky Past

The Scientist ARCHIVES

Become a Member of

Related Topics

Meet the Author

Ricki Lewis

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Skip the Wait for Protein Stability Data with Aunty

Products

Product News

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform

Nuclera eProtein Discovery System installed at leading Universities in Taiwan

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control